Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Cash-to-Debt : 0.01 (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Provectus Biopharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Provectus Biopharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Provectus Biopharmaceuticals's Cash-to-Debt or its related term are showing as below:

PVCT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.07 Max: No Debt
Current: 0.01

During the past 13 years, Provectus Biopharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.07.

PVCT's Cash-to-Debt is ranked worse than
98.94% of 1508 companies
in the Biotechnology industry
Industry Median: 6.505 vs PVCT: 0.01

Provectus Biopharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Provectus Biopharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Provectus Biopharmaceuticals Cash-to-Debt Chart

Provectus Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.03

0.39

0.01

0.03

Provectus Biopharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.01	0.06	0.12	0.03	0.01

Competitive Comparison of Provectus Biopharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Cash-to-Debt falls into.

Provectus Biopharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Provectus Biopharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.077	/	(3.001	+	0.025)
	=	0.03

Provectus Biopharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.018	/	(3.183	+	0.013)
	=	0.01

Provectus Biopharmaceuticals (OTCPK:PVCT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Provectus Biopharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932

Website

https://www.provectusbio.com

Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

Executives

Jeffrey Allen Morris	10 percent owner	1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines	officer: Chief Financial Officer	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing	director	2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass	officer: See Remarks	7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper	officer: Interim CEO, CFO, COO	7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter	director, officer: Chief Technology Officer	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv	director	191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams	10 percent owner	370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott	director, 10 percent owner, officer: President	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931